Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Maughan

Showing results (21-30 of 111) with videos related to

Pageof 12
Sort By:
Current Treatment Options in Oncology|January 26, 2018
Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell CarcinomaDavid M Gill, Andrew W Hahn, Peter Hale, et al.
Urologic Oncology|September 12, 2017
PD-1 checkpoint inhibition: Toxicities and managementAndrew W Hahn, David M Gill, Neeraj Agarwal, et al.
Drugs & Aging|February 21, 2019
Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint InhibitorsJohn Esther, Peter Hale, Andrew W Hahn, et al.
Clinical Genitourinary Cancer|April 27, 2020
Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell CarcinomaKyra McComas, Neeraj Agarwal, Glen Bowen, et al.
Current Treatment Options in Oncology|February 12, 2019
Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future DirectionJohn Esther, Benjamin L Maughan, Neysi Anderson, et al.
Clinical Genitourinary Cancer|December 18, 2024
Evaluation of Gemcitabine and Carboplatin Dosing in Patients With Cisplatin-Ineligible Metastatic Urothelial CarcinomaEleni Gamvroulas, Erin Bailey, Erik Harrington, et al.
Prostate Cancer and Prostatic Diseases|December 20, 2024
Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS)Benjamin L Maughan, Yanfang Liu, Suneel Mundle, et al.
Prostate Cancer|July 3, 2013
Emerging molecularly targeted therapies in castration refractory prostate cancerJesal C Patel, Benjamin L Maughan, Archana M Agarwal, et al.
American Journal of Clinical Pathology|June 28, 2024
Artificial intelligence chatbot vs pathology faculty and residents: Real-world clinical questions from a genitourinary treatment planning conferenceMatthew X Luo, Adam Lyle, Phillip Bennett, et al.
Cancer Treatment and Research Communications|February 12, 2019
Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and timeAndrew W Hahn, David Stenehjem, Roberto Nussenzveig, et al.
Pageof 12

Showing results (21-30 of 111) with videos related to

Sort By:
Pageof 12
Current Treatment Options in Oncology|January 26, 2018
Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell CarcinomaDavid M Gill, Andrew W Hahn, Peter Hale, et al.
Urologic Oncology|September 12, 2017
PD-1 checkpoint inhibition: Toxicities and managementAndrew W Hahn, David M Gill, Neeraj Agarwal, et al.
Drugs & Aging|February 21, 2019
Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint InhibitorsJohn Esther, Peter Hale, Andrew W Hahn, et al.
Clinical Genitourinary Cancer|April 27, 2020
Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell CarcinomaKyra McComas, Neeraj Agarwal, Glen Bowen, et al.
Current Treatment Options in Oncology|February 12, 2019
Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future DirectionJohn Esther, Benjamin L Maughan, Neysi Anderson, et al.
Clinical Genitourinary Cancer|December 18, 2024
Evaluation of Gemcitabine and Carboplatin Dosing in Patients With Cisplatin-Ineligible Metastatic Urothelial CarcinomaEleni Gamvroulas, Erin Bailey, Erik Harrington, et al.
Prostate Cancer and Prostatic Diseases|December 20, 2024
Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS)Benjamin L Maughan, Yanfang Liu, Suneel Mundle, et al.
Prostate Cancer|July 3, 2013
Emerging molecularly targeted therapies in castration refractory prostate cancerJesal C Patel, Benjamin L Maughan, Archana M Agarwal, et al.
American Journal of Clinical Pathology|June 28, 2024
Artificial intelligence chatbot vs pathology faculty and residents: Real-world clinical questions from a genitourinary treatment planning conferenceMatthew X Luo, Adam Lyle, Phillip Bennett, et al.
Cancer Treatment and Research Communications|February 12, 2019
Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and timeAndrew W Hahn, David Stenehjem, Roberto Nussenzveig, et al.
Pageof 12